



COPY OF PAPERS  
ORIGINALLY FILED

DT05 Rec'd PCT/PTO 22 AUG 2002

512100-2025  
PATENT

Rec'd  
164

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Berthold et al  
Serial No. : 10/031,529  
Filed : May 10, 2002  
For : PHARMACEUTICAL COMPOSITION  
Group Art Unit : 1623  
Confirmation No. : 6199

RECEIVED  
SEP 18 2002  
TECH CENTER 1600/2900

745 Fifth Avenue  
New York, New York 10151

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
DC 20231, on August 16, 2002

William F. Lawrence, Reg. No. 28,029

Name of Applicant, Assignee or Registered Representative

August 16, 2002

Date of Signature

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

It is respectfully requested that the filing receipt for the above-referenced  
application be corrected. Please delete "Trandermal Therapeutic System for Administering a  
Calcium Antagonist" as the title of the application, and insert "--Pharmaceutical Composition--"  
instead

Please refer to the attached copy of the filing receipt for this correction.


If there a fee associated with this procedure, please charge it to our Deposit

Account No. 50-0320.

Please forward the corrected document to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicant

By:   
William F. Lawrence  
Registration No. 28,029  
745 Fifth Avenue  
New York, New York 10036

COPY OF PATENTS  
ORIGINALLY FILED

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/031,529	05/10/2002	1623	1020	512100-2025	2	12	1

CONFIRMATION NO. 6199

William F Lawrence  
Frommer Lawrence & Haug  
745 Fifth Avenue  
New York, NY 10151

RECEIVED

SEP 18 2002

FILING RECEIPT



\*OC000000008220036\*

TECH CENTER 1600/2900

Date Mailed: 06/07/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Achim Berthold, Andernach, GERMANY;  
Walter Muller, Neuwied, GERMANY;  
Giovanni Gaviraghi, Verona, ITALY;

DOCKETED

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP00/06215 07/04/2000

## Foreign Applications

UNITED KINGDOM 9917290.0 07/22/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

## Title

~~Transdermal therapeutic system for administering a calcium antagonist~~

## Preliminary Class

Pharmaceutical composition

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).